BRPI0602275A - quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods for producing an antiproliferative effect in a warm-blooded animal and for treating a cancer in a warm-blooded animal and process for preparing a quinalizone derivative - Google Patents
quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods for producing an antiproliferative effect in a warm-blooded animal and for treating a cancer in a warm-blooded animal and process for preparing a quinalizone derivativeInfo
- Publication number
- BRPI0602275A BRPI0602275A BRPI0602275-8A BRPI0602275A BRPI0602275A BR PI0602275 A BRPI0602275 A BR PI0602275A BR PI0602275 A BRPI0602275 A BR PI0602275A BR PI0602275 A BRPI0602275 A BR PI0602275A
- Authority
- BR
- Brazil
- Prior art keywords
- warm
- derivative
- blooded animal
- quinazoline derivative
- quinazoline
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003246 quinazolines Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
DERIVADO DE QUINAZOLINA, COMPOSIçãO FARMACêUTICA, USO DE UM DERIVADO DE QUINAZOLINA, MéTODOS PARA PRODUZIR UM EFEITO ANTI-PROLIFERATIVO EM UM ANIMAL DE SANGUE QUENTE E PARA TRATAR UM CáNCER EM UM ANIMAL DE SANGUE QUENTE E PROCESSO PARA A PREPARAçãO DE UM DERIVADO DE QUINALIZONA A invenção refere-se a derivados de quinazolina de fórmula (I), em que cada um dentre R¬ 1¬, R¬ 3¬, R¬ 20¬, X¬ 1¬, X¬ 2¬, Z, W (a) e (q) tem qualquer um dos significados definidos na descrição; processos para sua preparação, composições farmacêuticas contendo os mesmos e seu uso na fabricação de um medicamento para uso como um agente antiproliferativo na prevenção ou tratamento de tumores que são sensíveis à inibição de receptor erbB tirosina quinases, particularmente EGFR tirosina quinase.QUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION, USE OF A QUINAZOLINE DERIVATIVE, METHODS TO PRODUCE AN ANTI-PROLIFERATIVE EFFECT ON A BLOOD ANIMAL AND TO TREAT A CANCER IN A HOT BLOOD ANIMAL FOR THE PREPARATION OF A QUINAZOLINE The invention relates to quinazoline derivatives of formula (I), wherein each of R¬ 1¬, R¬ 3¬, R¬ 20¬, X¬ 1¬, X¬ 2¬, Z, W (a) and (q) has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors that are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0602275-8A BRPI0602275A (en) | 2006-03-24 | 2006-03-24 | quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods for producing an antiproliferative effect in a warm-blooded animal and for treating a cancer in a warm-blooded animal and process for preparing a quinalizone derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0602275-8A BRPI0602275A (en) | 2006-03-24 | 2006-03-24 | quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods for producing an antiproliferative effect in a warm-blooded animal and for treating a cancer in a warm-blooded animal and process for preparing a quinalizone derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0602275A true BRPI0602275A (en) | 2007-11-27 |
Family
ID=38720875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0602275-8A BRPI0602275A (en) | 2006-03-24 | 2006-03-24 | quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods for producing an antiproliferative effect in a warm-blooded animal and for treating a cancer in a warm-blooded animal and process for preparing a quinalizone derivative |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0602275A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014135876A1 (en) | 2013-03-06 | 2014-09-12 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
-
2006
- 2006-03-24 BR BRPI0602275-8A patent/BRPI0602275A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014135876A1 (en) | 2013-03-06 | 2014-09-12 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| EP3342770A1 (en) | 2013-03-06 | 2018-07-04 | AstraZeneca AB | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414532A (en) | compound, process for preparing same, pharmaceutical composition, use of a compound, and method for producing an antiproliferative effect on a warm-blooded animal | |
| BRPI0414772A (en) | quinazoline derivative, compound, process for preparing a quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, and method for producing an antiproliferative effect on a warm-blooded animal | |
| BRPI0413066A (en) | quinazoline derivative, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof, of formula I, use and process for the preparation thereof, compound, pharmaceutical composition, and methods for producing an antiproliferative effect in an animal of warm blood, for the prevention or treatment of a tumor, to provide a selective egfr tyrosine kinase inhibitory effect, and to treat cancer in a warm-blooded animal | |
| BRPI0414735A (en) | quinazoline derivative, compound, pharmaceutical composition, use of quinazoline derivative, method for producing an antiproliferative effect on a warm-blooded animal, and process for the preparation of a quinazoline derivative | |
| BRPI0414488A (en) | quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods to produce an anti-proliferative effect in a warm-blooded animal, to prevent or treat tumors in a warm-blooded aminal, to provide a tyrosine kinase inhibitory effect of selective egfr in a warm-blooded animal and to treat cancer in a warm-blooded animal and process for the preparation of a quinazoline derivative | |
| BRPI0414489A (en) | quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, methods for producing an antiproliferative effect in a warm-blooded animal, for prevention or treatment of tumors in a warm sago aminal, to provide a tyrosine kinase inhibitory effect of egfr selective in a warm-blooded animal and to treat a cancer in a warm-blooded animal and, process for the preparation of a quinazoline derivative | |
| BR0308670A (en) | Quinazoline derivative or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of said derivative or salt thereof, method for producing an antiproliferative effect on a warm-blooded animal in need of such treatment, and , compound or a salt thereof. | |
| BRPI0511741A (en) | quinazoline derivative or a pharmaceutically acceptable salt thereof, pharmaceutical composition, process for preparing a quinazoline derivative or a pharmaceutically acceptable salt thereof | |
| BRPI0516093A (en) | quinazoline derivative, process for preparing it, pharmaceutical composition, use of a quinazoline derivative, and method for treating cell proliferative disorders in a warm-blooded animal | |
| BRPI0511760A (en) | gemcitabine treatment and an egfr inhibitor | |
| BR0213842A (en) | Quinazoline derivative or a pharmaceutically acceptable salt thereof, process for preparing the same, pharmaceutical composition, and use of the quinazoline derivative or pharmaceutically acceptable salt thereof | |
| BRPI0912475B8 (en) | compounds as kinase inhibitors, method for producing said compounds and pharmaceutical composition | |
| BRPI0416605A (en) | compound, process for preparing a compound, use of a compound, methods of inhibiting trk activity, treating or prophylaxis of cancer, and producing an antiproliferative effect on a warm-blooded animal and pharmaceutical composition | |
| BRPI0407834A (en) | compound, process for the manufacture thereof, composition, process for the manufacture thereof, method of treating or preventing a protein kinase-mediated disorder in an individual, use of a compound, assay to determine the activity of the compounds, and method inhibiting the activity or function of a protein kinase | |
| BRPI0512796A (en) | compound, process for preparing same, pharmaceutical composition, use of a compound, and methods for producing an inhibitory effect of b-raf, and an anticancer effect on a warm-blooded animal, and for treating a disease. | |
| BRPI0418351A (en) | compound or a pharmaceutically acceptable salt thereof, methods of limiting cell proliferation in a human or animal, treating a human or animal suffering from cancer, treating cancer prophylaxis, treating a human or animal suffering from a disease treatment of a human or animal suffering from a proliferative cancer treatment disease, for the treatment of cancer-associated infections, for the prophylactic treatment of cancer-associated infections, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, method of inhibiting chk1 kinase, and process for preparing a compound or a pharmaceutically acceptable salt thereof | |
| ATE353888T1 (en) | CHINAZOLINE DERIVATIVES | |
| BR0215312A (en) | Use of a compound, method for inhibiting aurora kinase in a warm-blooded animal, compound, pharmaceutical composition, and process for preparing a compound | |
| BRPI0410563A (en) | Process pyrazole quinazoline derivatives for their preparation and their use as kinase inhibitors | |
| BRPI0514679A (en) | compound, process for preparing same, pharmaceutical composition, use of a compound, and methods for producing an inhibitory effect of b-raf and an anticancer effect on a warm-blooded animal, and for treating a disease or condition | |
| NO20061415L (en) | quinazoline | |
| BR0315988A (en) | Amino-substituted dihydropyrimidate [4,5-d] pyrimidinone derivatives, their production and use as pharmaceutical agents | |
| BRPI0607927A2 (en) | pyrazol pyrimidine derivatives | |
| BRPI0618552B8 (en) | pyrimidine derivative compounds linked to oxygen, pharmaceutical composition that includes said compounds, method of synthesis of the compounds and therapeutic uses thereof | |
| BRPI0512075A (en) | compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |